Product Program year 2025 Source: CMS Open Payments

Myrbetriq

Drug Urology

NDC 0469-2601-30

Open in the dashboard

General payments

$6,013,077

267,393 payments

Research payments

$666,275

370 payments

Through program year 2025, $6,013,077 in general payments and $666,275 in research payments were reported against Myrbetriq (Urology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $8,182 19
2025 Research $76,405 26
2024 General $98,949 2,675
2024 Research $20,952 15
2023 General $554,378 31,361
2023 Research $9,385 16
2022 General $713,080 41,130
2022 Research $15,882 29
2021 General $1,166,131 68,291
2021 Research $12,554 17
2020 General $804,343 37,239
2020 Research $177,250 43
2019 General $2,668,013 86,678
2019 Research $353,846 224

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $5,677,411 267,270 payments
  2. Astellas Pharma Global Development $283,266 108 payments
  3. Astellas Pharma Inc $38,007 8 payments
  4. Astellas Pharma Europe BV $14,393 7 payments
Top recipients General payments · program year 2025
  1. Elaine Urbina Pediatric Cardiology · Cincinnati, OH $3,879 47% · 1 payment
  2. Philip Walson Clinical Pharmacology · Cincinnati, OH $2,775 34% · 1 payment
  3. Beth Drzewiecki Pediatric Urology · Boston, MA $1,208 15% · 1 payment
  4. Deborah Schrager Obstetrics & Gynecology · Philadelphia, PA $28 <1% · 1 payment
  5. Anne Torna Obstetrics & Gynecology · Philadelphia, PA $28 <1% · 1 payment

The top 5 of 19 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatric Cardiology Pediatrics $3,879 47% · 1 practitioner
  2. Clinical Pharmacology $2,775 34% · 1 practitioner
  3. Pediatric Urology Urology $1,208 15% · 1 practitioner
  4. Obstetrics & Gynecology $138 2% · 6 practitioners
  5. Nurse Practitioner, Obstetrics & Gynecology Nurse Practitioner $59 <1% · 3 practitioners

The top 5 of 10 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Ohio $6,654 81% · 2 recipients
  2. Massachusetts $1,208 15% · 1 recipient
  3. New Jersey $86 1% · 4 recipients
  4. Pennsylvania $77 <1% · 3 recipients
  5. New York $57 <1% · 3 recipients

The top 5 of 8 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,973,900

Prescriptions dispensed, refills included

Drug cost

$1,896,183,997

Paid at the pharmacy, in all

Prescribers

68,875

With 11 or more claims of it

Medicare Part D drugs matched to MYRBETRIQ, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Myrbetriq Mirabegron Same name 68,875 2,973,900 $1,896,183,997

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Emily Levandusky Physician Assistant NY 2,740 $2,071,571 None on record
Armen Kassabian Urology CA 1,986 $914,154 None on record
Brian Crotzer Physician Assistant NY 1,981 $1,396,572 None on record
Robert Pearlstein Internal Medicine PA 1,387 $287,650 None on record
Felix Yip Urology CA 1,225 $766,269 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
267,393 general · 370 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record